ClinicalTrials.Veeva

Menu

Prospective Cohort Study of a Population at Risk of Psychotic Transition (EPEDIP)

C

Centre Hospitalier Esquirol

Status

Active, not recruiting

Conditions

At-risk Mental States

Treatments

Other: Observational

Study type

Observational

Funder types

Other

Identifiers

NCT06539611
2024-A00720-47

Details and patient eligibility

About

In psychiatry, insight is the patient's awareness of his or her disorder or symptom. Lack of insight also seems to be associated with the presence of anxiety-depressive symptoms.

There are several forms of insight:

  • clinical" insight, which is the perception of suffering from a given pathology or symptoms
  • cognitive insight (CI), which is the ability to analyse or judge one's own thoughts, beliefs and judgements
  • and the insight of cognitive disorders or the subjective perception of the cognitive alterations (or cognitive symptoms) presented. In this study, the investigators will refer to this dimension as 'subjective cognitive complaint' (SCP), in order to differentiate it from cognitive insight, the name of which may lead to confusion.

In schizophrenic disorders, there is a positive correlation between the subjective cognitive complaint SCC, and certain alterations in the neurocognitive assessment, including the attentional dimension. There are scales for collecting SCC in psychotic disorders, such as the SSTICS. To date, there is no scale validated specifically for the UHR population. Thus, the scales used (STICSS, SCoRS, etc.) are validated in populations presenting a characterised psychotic state. Objective impairment is measured during a neurocognitive assessment carried out by a specialised professional: a clinical psychologist specialised in neuropsychology. The cognitive performance of UHR patients is impaired, particularly in terms of cognitive flexibility and self-perception of cognitive disorders, and there may be a discrepancy between the complaint, the objective disorders and their identification as "disorders" by the patient.

Despite this discrepancy, to the investigators knowledge no study to date has investigated a possible link between SCC and psychotic transition in this population. Thus, it is not known whether social class may be a factor in exposure to transition, or whether there is a link at all between social class and risk of transition. The aim of this study is to determine psychotic transition in UHR in a 30 months follow-up, and to determine whether there is a link between SCC and transition.

Enrollment

125 estimated patients

Sex

All

Ages

15 to 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female ;
  • Be aged between 15 and 30 ;
  • Being assessed by the eDIP (early intervention team "équipe de détection et d'intervention précoce") ;
  • Sufficient level of French to understand and express yourself orally and in writing;
  • For adults:

Patients who have received informed information about the study and who have signed a consent to participate in the study;

- For minors: Patient who has received informed information about the study and who has signed, as well as the holders of parental authority the minor's consent to participate in the study.

Exclusion criteria

  • Have already presented a First Psychotic Episode;
  • Previous diagnosis of schizophrenia, psychotic disorder or bipolar disorder;
  • Being on antipsychotic treatment at the time of inclusion ;
  • Known intellectual disability ;
  • Pregnant or breast-feeding woman;
  • Minors and adults under legal protection.

Trial contacts and locations

1

Loading...

Central trial contact

Mirvat HAMDAN-DUMONT, MD, MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems